RQA membership is a great way to connect with your QA colleagues.
More information
Join the community - networking, discussion and more. Open to all.
More information
Could you write an interesting article for the RQA community?
More informationThe International Coalition of Medicines Regulatory Authorities (ICMRA) convened a virtual meeting of regulators from around the world on 14 May 2020 to discuss high-level policy issues and regulatory requirements to respond to the ongoing COVID-19 pandemic. The strategic meeting underlined the need and commitment by global regulators to cooperate and align their approaches to clinical trial management, medicine supply issues and pharmacovigilance in light of the medical emergency presented by COVID-19.
PRAC concludes review of new information on the known risk of breast cancer with hormone replacement therapy
Number 21 OECD Position Paper Regarding Possible Influence of Sponsors on Conclusions of GLP Studies
Terry Madigan, 13th May During the Covid-19 pandemic you may need to adjust how you operate, for example using temporary process deviations and temporary staff. Such changes should be documented either as deviations, change controls or similar and incorporate quality risk management principles as described in the EU Guidelines on Good Distribution Practice for finished products.
Kiernan Trevett, Posted on:7 May 2020 - Many marketing authorisation holders (MAHs) sponsor and run a wide variety of programmes that are often internally termed a ‘patient support programme’ (PSP) and we are often asked by industry about the expectations for the collection of safety data from these programmes.
What you should do when transferring people’s personal data between the UK and the EU/EEA.
Clinical Safety & Pharmacovigilance Regulatory Intelligence Review
The MHRA has released information for members of the public, patients, professionals and industry about COVID-19 tests and testing kits....
As researchers race to develop vaccines and therapeutics against COVID-19, EMA has published an overview of how the Agency will accelerate its regulatory procedures so that marketing authorisations of safe, effective and high-quality COVID-19 related medicines can be granted as soon as possible.
The Good Pharmacovigilance Practice (GPvP) Symposium 2020, held on 11 February in London and attended by 380 delegates, launched the weeklong series of events led by the Inspectorate as part of the MHRA Good Practice Symposia week.